The KCNB1 antibody is a crucial tool in neuroscience research, targeting the KCNB1-encoded Kv2.1 protein, a voltage-gated potassium channel critical for neuronal excitability and signaling. Kv2.1 regulates action potential repolarization, calcium homeostasis, and synaptic plasticity, primarily in the brain. Dysfunctional Kv2.1 channels are linked to neurodevelopmental disorders, epilepsy, and encephalopathies. KCNB1 antibodies enable the detection and localization of Kv2.1 in tissues or cell cultures via techniques like Western blot, immunohistochemistry, or immunofluorescence. They aid in studying channel expression changes in disease models, genetic mutations (e.g., gain- or loss-of-function variants), and therapeutic responses. Recent studies highlight KCNB1 antibody applications in exploring channelopathies, such as early-infantile epileptic encephalopathy, and in validating Kv2.1 as a biomarker or drug target. These antibodies are typically raised in rabbits or mice, with validation for specificity against Kv2.1’s conserved regions. Ongoing research leverages KCNB1 antibodies to unravel Kv2.1’s role in neurodegeneration and metabolic stress responses, underscoring their importance in both basic and clinical neuroscience.